StockData
IGC Pharma, Inc. logo

IGC Pharma, Inc. (IGC) stock

IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3021% above fair value
$0.18−0.01 (-7.24%)

Close on Nov 12, 2026Market cap $19.07MP/E –Yield –

IGC Pharma gross margin

Gross margin is gross profit as a percentage of revenue.

IGC Pharma's gross margin for the twelve months ending Jun 30, 2026 was 21.9%. For fiscal 2025 it was 48.7%, against 54.5% the year before. The highest annual figure on record is 54.5% in fiscal 2024.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Mar 31, 202548.7%−5.8
FY2024Mar 31, 202454.5%+6.0
FY2023Mar 31, 202348.5%−0.3
FY2022Mar 31, 202248.9%+36.3
FY2021Mar 31, 202112.6%+9.8
FY2020Mar 31, 20202.8%+0.2
FY2019Mar 31, 20192.6%−1.2
FY2018Mar 31, 20183.7%−33.9
FY2017Mar 31, 201737.6%+24.4
FY2016Mar 31, 201613.2%+5.7
FY2015Mar 31, 20157.5%−9.2
FY2014Mar 31, 201416.8%−2.3
FY2013Mar 31, 201319.1%+33.8
FY2012Mar 31, 2012-14.7%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q1 FY2027CQ2 2026Jun 30, 202618.1%−28.8
Q4 FY2026CQ1 2026Mar 31, 202617.4%−29.3
Q3 FY2026CQ4 2025Dec 31, 202512.6%−27.9
Q2 FY2026CQ3 2025Sep 30, 202551.8%+3.8
Q1 FY2026CQ2 2025Jun 30, 202547.0%−13.0
Q4 FY2025CQ1 2025Mar 31, 202546.7%−11.3
Q3 FY2025CQ4 2024Dec 31, 202440.5%−24.7
Q2 FY2025CQ3 2024Sep 30, 202448.1%−11.7
Q1 FY2025CQ2 2024Jun 30, 202459.9%+14.0
Q4 FY2024CQ1 2024Mar 31, 202458.0%+20.0
Q3 FY2024CQ4 2023Dec 31, 202365.2%+34.5
Q2 FY2024CQ3 2023Sep 30, 202359.8%−7.0
Q1 FY2024CQ2 2023Jun 30, 202345.9%−21.0
Q4 FY2023CQ1 2023Mar 31, 202338.0%−17.8
Q3 FY2023CQ4 2022Dec 31, 202230.7%−12.9
Q2 FY2023CQ3 2022Sep 30, 202266.8%−1.0
Q1 FY2023CQ2 2022Jun 30, 202267.0%+33.2
Q4 FY2022CQ1 2022Mar 31, 202255.7%+22.4
Q3 FY2022CQ4 2021Dec 31, 202143.7%+30.7
Q2 FY2022CQ3 2021Sep 30, 202167.9%+47.1
Q1 FY2022CQ2 2021Jun 30, 202133.8%+25.9
Q4 FY2021CQ1 2021Mar 31, 202133.3%−21.8
Q3 FY2021CQ4 2020Dec 31, 202013.0%+7.7
Q2 FY2021CQ3 2020Sep 30, 202020.8%+19.3
Q1 FY2021CQ2 2020Jun 30, 20207.9%+5.4
Q4 FY2020CQ1 2020Mar 31, 202055.2%+53.4
Q3 FY2020CQ4 2019Dec 31, 20195.2%+1.7
Q2 FY2020CQ3 2019Sep 30, 20191.5%−0.7
Q1 FY2020CQ2 2019Jun 30, 20192.5%−0.4
Q4 FY2019CQ1 2019Mar 31, 20191.8%+8.4
Q3 FY2019CQ4 2018Dec 31, 20183.5%−1.6
Q2 FY2019CQ3 2018Sep 30, 20182.2%−28.4
Q1 FY2019CQ2 2018Jun 30, 20182.8%−84.2
Q4 FY2018CQ1 2018Mar 31, 2018-6.7%−14.5
Q3 FY2018CQ4 2017Dec 31, 20175.1%−46.1
Q2 FY2018CQ3 2017Sep 30, 201730.6%–
Q1 FY2018CQ2 2017Jun 30, 201787.0%–
Q4 FY2017CQ1 2017Mar 31, 20177.8%–
Q3 FY2017CQ4 2016Dec 31, 201651.2%–

More IGC Pharma figures

See a number that looks wrong?